Sugi Predict

Sugi Predict / Compounds / SCHEMBL15020171

SCHEMBL15020171

SCHEMBL15020171

CC(C)(C)CCC(=O)Oc1c(NC(=O)OCc2ccccc2)cccc1B1OC(C)(C)C(C)(C)O1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.43
▸ RAB9A P51151 2/20 0.43
▸ CASP3 P42574 2/20 0.40
▸ MAOB P27338 1/20 0.36
▸ PLAU P00749 1/20 0.36
▸ PTPN1 P18031 1/20 0.36
▸ HDAC3 O15379 2/20 0.36
▸ HDAC1 Q13547 2/20 0.36
▸ HDAC2 Q92769 2/20 0.36
▸ MGLL Q99685 1/20 0.35
▸ TRPV1 Q8NER1 1/20 0.35
▸ POLB P06746 1/20 0.34
▸ ELANE P08246 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ LIPG Q9Y5X9 1/20 0.34
▸ LIPE Q05469 1/20 0.34
▸ HDAC4 P56524 1/20 0.34
▸ HDAC7 Q8WUI4 1/20 0.34
▸ HDAC10 Q969S8 1/20 0.34
▸ HDAC11 Q96DB2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15019749 0.88 NPC1 (0.47) NPC1RAB9ACASP3MAOBPLAU
SCHEMBL28910668 0.86 AAK1 (0.40) POLBLIPE
Water SCHEMBL28534998 0.81 NPC1 (0.50) NPC1RAB9ACASP3MAOBPLAU
SCHEMBL25320467 0.80 NPC1 (0.49) NPC1RAB9ACASP3PLAUPTPN1
SCHEMBL28543429 0.77 NPC1 (0.36) NPC1RAB9ASMN1; SMN2LIPE
SCHEMBL15091822 0.75 NPC1 (0.44) NPC1RAB9ACASP3PLAUPTPN1
SCHEMBL6652035 0.75 AAK1 (0.42) POLBLIPE
SCHEMBL15092118 0.74 NPC1 (0.45) NPC1RAB9ACASP3MAOBPLAU
SCHEMBL4566819 0.72 POLB (0.51) NPC1RAB9ACASP3MAOBTRPV1
SCHEMBL22436216 0.71 TRPV1 (0.45) NPC1RAB9ACASP3PTPN1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107074820-B GLP-1 receptor modulators 赛尔基因第二国际有限公司 2021-05-18 — — CN disclosed
CN-112457301-A Novel GLP-1 receptor modulators 赛尔基因第二国际有限公司 2021-03-09 — — CN disclosed
EP-3008056-B1 NOVEL GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-12-09 — — EP disclosed
EP-3172199-B1 PYRIMIDINE DERIVATIVES AS GLP-1 RECEPTOR MODULATORS CELGENE INT II SARL (CH) 2020-07-01 — — EP disclosed
US-10259823-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2019-04-16 — — US disclosed
US-9839664-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-12-12 — — US disclosed
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-11-02 — — US disclosed
US-20170216392-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2017-08-03 — — US disclosed
EP-3172199-A1 NOVEL GLP-1 RECEPTOR MODULATORS Receptos, Inc. (US) 2017-05-31 — — EP disclosed
US-9598430-B2 GLP-1 receptor modulators CELGENE INTERNATIONAL II SÀRL (CH) 2017-03-21 — — US disclosed
US-9260427-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2016-02-16 — — US disclosed
US-20160038487-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2016-02-11 — — US disclosed
WO-2016015014-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2016-01-28 — — WO disclosed
US-9187522-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2015-11-17 — — US disclosed
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-02-05 — — US disclosed
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS LLC 2015-01-08 — — US disclosed
EP-2791112-A2 CARBOXYLIC ACID DERIVATIVES COMPRISING FOUR CYCLES ACTING AS GLP-1 RECEPTOR MODULATORS FOR THERAPY OF DISEASES SUCH AS DIABETES Receptos, Inc. (US) 2014-10-22 — — EP disclosed
US-8778923-B2 GLP-1 receptor modulators RECEPTOS, INC. (US) 2014-07-15 — — US disclosed
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-07-11 — — US disclosed
WO-2013090454-A2 NOVEL GLP-1 RECEPTOR MODULATORS RECEPTOS, INC. (US) 2013-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170313717-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R NPC1 2943/4885RAB9A 609/4885CASP3 1376/4885
US-20170216392-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R NPC1 3488/4885RAB9A 989/4885CASP3 1733/4885
US-20130178420-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R NPC1 2451/4885RAB9A 733/4885CASP3 1409/4885
US-20150038416-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R NPC1 2451/4885RAB9A 733/4885CASP3 1409/4885
US-20160038487-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R NPC1 3488/4885RAB9A 989/4885CASP3 1733/4885
US-10259823-B2 GLP-1 receptor modulators GLP1R, GIPR, GCGR NPC1 3058/4885RAB9A 661/4885CASP3 1177/4885
US-20150011527-A1 NOVEL GLP-1 RECEPTOR MODULATORS GLP1R, GIPR, NPY1R NPC1 2943/4885RAB9A 609/4885CASP3 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.